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Abstract
FIGO (the International Federation of Gynecology and Obstetrics) supports assisted 
reproductive technologies (ART) to achieve pregnancy and supports their availability 
in all nations. However, the increased frequency of preterm birth must be taken into 
account. Therefore, before in vitro fertilization (IVF) is started, other approaches, in-
cluding expectant management, should be considered. Single embryo transfer is the 
best approach to ensure a live, healthy child. However, increased risks for preterm 
birth are also associated with a singleton IVF pregnancy and should be discussed 
and contrasted with spontaneous conception. Increased preterm birth and other ad-
verse pregnancy outcomes in singleton IVF cycles warrant investigations to elucidate 
and mitigate. Minimizing embryo manipulation during cell culture is recommended. 
Increased risk of preterm birth and other pregnancy complications in ART could re-
flect the underlying reasons for infertility. This information should be discussed and 
further explored.
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1  |  INTRODUC TION
Assisted reproductive technology (ART) is an essential compo-
nent of infertility treatment. FIGO (the International Federation of 
Gynecology and Obstetrics) supports WHO in considering child-
bearing a human right that should be accessible in all nations. The 
social stigma of childlessness can lead to isolation and abandonment 
of women.1 ART accounts for approximately 1%– 2% of all pregnan-
cies globally and as much as 7% in certain countries.2 However, ART 
is also a significant risk factor for preterm birth, both in high- income 
and low– middle- income countries, and even in situations where sin-
gle embryo transfer (SET) is applied.3,4
Recommendation: FIGO supports ART to achieve pregnancy and 
supports its availability in all nations. However, the increased frequency 
of preterm birth and other pregnancy complications must be considered 
when starting ART.
2  |  TARGETED USE OF A SSISTED 
REPRODUC TIVE TECHNOLOGY
In vitro fertilization (IVF) should only be used if it is indispensable, i.e., 
if spontaneous conception or conception using less invasive methods 
have failed. This can be the case in infertile couples or individuals with 
diagnoses such as blocked tubes or severe male infertility that rule out 
spontaneous fertility chances. Otherwise, a prognosis for spontaneous 
conception could help.5 In case of good prognosis, there might be ben-
efit from expectant management or less invasive treatments with tubal 
flushing or intra- uterine insemination. Lifestyle interventions should 
also be considered for appropriate women. For example, in women 
with anovulation due to polycystic ovary syndrome, ovulation induc-
tion can be the first- line treatment. There are also other indications for 
IVF that are not covered in this document.
Recommendation: Before IVF is started, other approaches, including 
expectant management and other less invasive treatments, should be 
considered.
3  |  SINGLE EMBRYO TR ANSFER IN 
A SSISTED REPRODUC TIVE TECHNOLOGY
The US Centers for Disease Control and Prevention (CDC) states 
that double embryo transfer in ART results in a 27%– 33% twin rate, 
whereas SET results in a 1% twin rate.5,6 In addition, transferring 
multiple embryos is unequivocally correlated with preterm birth.4,6 
This strategy has long been advocated but has not been pursued 
rigorously. Given that ART is increasingly performed worldwide, in-
creased rates of twins will continue unless SET is widely utilized. We 
realize the global differences, but there should never be a standard 
procedure to transfer multiple embryos.
Recommendation: In treatment with IVF, single embryo transfer 
is the best approach to prevent multiple pregnancies and subsequent 
preterm birth, thus maximizing the chance of having a healthy live child.
4  |  PREGNANCY COMPLIC ATIONS IN ART
Less appreciated than in multiple gestation pregnancies is that sin-
gleton IVF pregnancies are also associated with increased preterm 
birth (two- fold), stillbirths, and intrauterine growth restriction. In 
addition, neonatal Intensive Care Unit (NICU) admissions are also 
increased.7
Meta- analyses of singleton IVF pregnancies have shown up to 
10.9% preterm birth rates (<37 weeks of gestation) versus 6.4% in a 
comparison group delivered at full term.8 Thus, singleton IVF preg-
nancy remains a risk factor for early preterm birth even after adjust-
ment for other risk factors such as maternal age, smoking, or prior 
surgical procedures for cervical intraepithelial neoplasia or infertil-
ity.8,9 Similarly, infertility or subfertility without ART is associated 
with increased adverse pregnancy outcomes compared with spon-
tanteous pregnancies.1 Association of ART with preterm birth is also 
evident from conception with intrauterine insemination or ovulation 
induction, as singleton pregnancies resuting from these treatments 
do not have increased preterm birth rates.3
Recommendation: Increased risks for preterm birth are associated 
with singleton IVF. This information should be discussed and contrasted 
with spontaneous conception.
The increased risk for preterm birth in singleton IVF pregnan-
cies may reflect embryo manipulation inherent in successful ART. 
Embryo culture, freezing/thawing procedures and endometrial 
transfer itself may impair implantation or the ability to maintain a 
pregnancy and influence the neonatal outcome.10 Significant differ-
ences in preterm birth rates and other adverse pregnancy outcomes 
are observed when comparing different culture media or fresh 
and frozen transfer, perhaps leading to abnormal placentation.9,11 
Abnormalities of placental function as an explanation are suggested 
by increased maternal β- hCG and decreased pregnancy- associated 
plasma during early pregnancy.12,13
Recommendation: Increased preterm birth and other adverse preg-
nancy outcomes in singleton IVF cycles warrant investigations to eluci-
date and mitigate. Therefore, minimizing embryo manipulation during 
cell culture is recommended.
An alternative explanation for increased preterm birth and other 
adverse outcomes in singleton IVF cycles is that these outcomes 
could reflect the underlying reason why ART infertility was required 
to achieve a pregnancy. By analogy, birth defects are increased 30% 
(odds ratio 1.3) in offspring conceived using IVF or intra- cytoplasmic 
sperm injection (ICSI).14,15 Moreover, birth defects are increased by 
20% in subfertile women whose time to conceive is delayed (>1 year) 
but who never required IVF or ICSI.16
Recommendation: Increased risks for preterm birth and other preg-
nancy complications in ART could reflect the underlying reasons for in-
fertility. This information should be discussed.
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